Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The study will be conducted at the University of Southern California, San Francisco, and the Memorial Sloan Kettering Cancer Center in New York
It has been provided verbal confirmation; formal written approval is expected within the next two weeks
Results from study of PQ Birch are expected in the second half of this year
The company’s Parsortix system can be used to measure the expression of androgen receptor splice variant 7
The proceeds from the share sale will be used to progress two phase II clinical trials
It will be a base for medical and scientific communications staff
Dr Juhana Heinonen will join the business in January from AstraZeneca
Hospital operator's shares surged as in-patient data revealed it be head and shoulders above the competition
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.